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Abstract: Despite intensive research on testosterone therapy for older men, important questions 
remain unanswered. The evidence clearly indicates that many older men display a partial androgen 
deﬁ  ciency. In older men, low circulating testosterone is correlated with low muscle strength, with 
high adiposity, with insulin resistance and with poor cognitive performance. Testosterone replace-
ment in older men has produced beneﬁ  ts, but not consistently so. The inconsistency may arise from 
differences in the dose and duration of testosterone treatment, as well as selection of the target 
population. Generally, studies reporting anabolic responses to testosterone have employed higher 
doses of testosterone for longer treatment periods and have targeted older men whose baseline 
circulating bioavailable testosterone levels were low. Most studies of testosterone replacement 
have reported anabolic that are modest compared to what can be achieved with resistance exercise 
training. However, several strategies currently under evaluation have the potential to produce 
greater anabolic effects and to do so in a safe manner. At this time, testosterone therapy can not 
be recommended for the general population of older men. Older men who are hypogonadal are at 
greater risk for the catabolic effects associated with a number of acute and chronic medical condi-
tions. Future research is likely to reveal beneﬁ  ts of testosterone therapy for some of these special 
populations. Testosterone therapy produces a number of adverse effects, including worsening 
of sleep apnea, gynecomastia, polycythemia and elevation of PSA. Efﬁ  cacy and adverse effects 
should be assessed frequently throughout the course of therapy.
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Testosterone physiology in health
In young adult men, the hypothalamic-pituitary-gonadal axis regulates the circu-
lating concentration of testosterone. The hypothalamic pulse generator secretes a 
pulse of gonadotropin releasing hormone (GnRH) approximately every 90 minutes 
(Reyes-Fuentes and Veldhuis 1993). GnRH is secreted into the hypothalamic-pituitary 
portal circulation where it stimulates pituitary secretion of luteinizing hormone (LH) 
(Veldhuis et al 1990) into the systemic circulation. LH reaches the testes and promotes 
both tonic and episodic Leydig cell secretion of testosterone.
Nearly all of the testosterone circulating in the blood is bound to sex hormone-binding 
globulin (SHBG) or albumin. The afﬁ  nity of SHBG for testosterone is about 1,000-fold 
higher than the afﬁ  nity of albumin for testosterone (Pardridge et al 1985). Thus the com-
bined free (1%–2%) and albumin-bound fractions of testosterone are considered to be 
bioavailable (Manni et al 1985). Bioavailable testosterone in acts upon multiple target 
tissues and completes the feedback loop inhibiting GnRH and LH secretion. 
The serum testosterone concentration displays both circadian and ultradian rhythms. 
The circadian rhythm results in peak testosterone serum concentrations during the early 
morning hours. In contrast, the ultradian rhythm has a cycle whereby the serum testos-
terone concentration ﬂ  uctuates approximately every 90 minutes. This ultradian rhythm 
represents the burst-like secretory pattern of testosterone, which is superimposed on 
testosterone’s basal or tonic secretion.
In young adult health, the feedforward (GnRH stimulates LH which stimulates 
testosterone secretion) and feedback (free or bioavailable testosterone inhibits Clinical Interventions in Aging 2007:2(4) 562
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release of GnRH and LH) components of the hypothalamic-
pituitary-gonadal axis maintain the serum total testosterone 
concentration within a “normal” range of 450–1,000 ng/dL. 
The mean serum total testosterone concentration for healthy 
young adults approximates 650 ng/dL.
Testosterone in older men
Unlike female menopause, the decline in testosterone 
serum concentration in men is gradual, and there is much 
inter-individual variability. Serum testosterone concentra-
tions decline steadily after young adulthood, and by age 
of 80 years, the testosterone secretion rate decreases to 
approximately half that of a younger man (Tenover et al 
1987; Mulligan et al 1995).
The decrease in bioavailable-testosterone appears to be 
greater than the decline in total testosterone with advanc-
ing age, due to an age-related increase in SHBG (Rubens 
et al 1974). The decline in testosterone with aging has been 
referred to by a variety of names including male menopause, 
climacteric, viropause, andropause, ADAM (androgen 
deﬁ  ciency in aging men), or age-associated hypogonadism. 
Longitudinal studies conﬁ  rm a decline in testosterone with 
aging, as has been reported earlier in cross-sectional studies 
(Morley et al 1997; Feldman et al 2002).
With age, changes that contribute to hypogonadism occur 
in both the hypothalamus and testes. The rise in LH following 
a decrease in testosterone is considerably blunted with age 
(Korenman et al 1990; Veldhuis et al 2001). This is likely due 
to failure of the hypothalamus to generate an appropriate burst of 
GnRH secretion (Veldhuis et al 1994; Mulligan et al 1999). The 
speciﬁ  c mechanism may be an age-related increased sensitivity 
of the hypothalamic-pituitary unit to the negative feedback effect 
of testosterone (Winters et al 1984). In older men, the decline 
in circulating testosterone also correlates with changes in the 
testes, speciﬁ  cally a decline in Leydig cell number (Neaves et al 
1984), development of vacuolizations and lipofuscin within the 
Leydig cells, and decreased Leydig cell secretion of testosterone 
in response to provocative stimulation with human chorionic 
gonadotrophin (Harman and Tsitouras 1980).
The decline in bioavailable testosterone may be at least 
partially responsible for the decreased muscle mass, osteo-
porosis, mood disturbances, and frailty seen in older men 
(Nunez 1982).
Prevalence of age-associated 
hypogonadism
The criteria for low testosterone are the same regardless 
of age. Symptomatic men with a total serum testosterone 
concentration less that 200 ng/dL are deﬁ  nitely hypogonadal, 
while those with a concentration between 200 and 300 ng/dL 
are probably hypogonadal. The prevalence of hypogonadism 
increases with advancing age; the odds ratio of hypogonadism 
is greater with each 10-year increase in age. Longitudinal 
studies in speciﬁ  c geographic areas of the United States 
and some small cross-sectional studies have demonstrated a 
decline in testosterone occurring as early as age 30, but usu-
ally testosterone levels remain within normal limits until men 
reach age 60 (Belanger et al 1994; Morley et al 1997). The 
prevalence of low serum total testosterone among men aged 
45 years or older has been estimated to be 39% (Mulligan 
et al 2006). The prevalence of symptomatic hypogonadism 
is considerably lower, estimated as 6%–12% in a group of 
men aged 40–60 years in the report of the Massachusetts 
Male Aging Study (Araujo et al 2004).
Beneﬁ  cial effects of testosterone
on mood and cognition
Low serum testosterone concentration in older men is associ-
ated with depression (Shores et al 2005). However, most trials 
of testosterone replacement have not shown improvement 
in depression. Two small studies in younger hypogonadal 
men did show short term improvement in depression with 
testosterone supplementation, but this effect has not been 
reproduced in older men (Pope et al 2003). The age of onset 
of depression may also be a factor in response to testosterone. 
Perry et al (2002) reported that 6 weeks of testosterone treat-
ment improved depression scores in men who had onset of 
depression after the age of 45 years, but not in men whose 
depression started at a younger age.
Higher bioavailable testosterone levels are associated 
with better performance in cognitive tests (Barett-Connor 
et al 2004). Short-term trials in healthy eugonadal older 
men have shown improvement in verbal and spatial memory 
(Cherrier et al 2001; Gray et al 2005). However, longer trials 
have produced mixed results. Haren et al (2005) reported no 
improvement in cognition or memory. In a recent study by 
Cherrier et al (2006), older men were treated for 6 weeks 
with testosterone at doses of 50, 100 or 300 mg/week. Inter-
estingly, improvements in verbal and spatial memory were 
observed only with the intermediate dose.
Beneﬁ  cial effects of testosterone
on muscle and bone 
Testosterone produces substantial anabolic effects in young 
and middle-aged hypogonadal men (Bhasin et al 2001). In 
contrast, the anabolic effects of testosterone replacement Clinical Interventions in Aging 2007:2(4) 563
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therapy in older men have been harder to demonstrate. 
Among the many published trials of testosterone in older 
men, some report strength gains and some do not. Only a 
few report strength gains that can be considered substantial 
in comparison to the beneﬁ  ts of resistance exercise training. 
In most cases, the studies reporting signiﬁ  cant strength gains 
were performed in hypogonadal subjects and employed a 
higher dose of testosterone, for a longer duration.
In a recent report, Nair et al (2006) describe treating a 
group of hypogonadal men for 24 months with a transdermal 
testosterone at a dose of 35 mg/week and ﬁ  nding no increase 
in strength. However, 35 mg/week is less than a replacement 
dose and resulted in only a 30% increase in the circulating 
testosterone concentration. Studies by Brill et al (2002), 
Clague et al (1999), Kenny et al (2001), and Snyder et al 
(1999) also report small increases in strength. Brill et al 
treated older men for 1 month with 5 mg testosterone/day 
by patch and found an improvement in stair climb time, but 
no increase in strength. Clague et al treated men aged 60 or 
more with total T of 400 ng/dL or less were treated with 
200 mg testosterone enanthate every two weeks by i.m. 
injection for 3 months and found no signiﬁ  cant increase in 
strength. Kenny et al (2001) treated hypogonadal and low-
normal older men with 5 mg testosterone/day by patch for 
1 year and found a 38% increase in strength with testosterone, 
but surprisingly also a 27% increase with placebo, with no 
signiﬁ  cant difference between the two groups. Snyder et al 
(1999) treated older hypogonadal and eugonadal men for 
36 months with 6 mg testosterone/day by patch and found 
no increase in strength.
Several investigators have reported that testosterone 
caused moderate increases in strength; increases that are 
signiﬁ  cant, but are still below than what can be obtained 
through resistance exercise training. Wang et al (2000) 
treated younger and older men (aged 19–68) with total T 
of 300 ng/dL or less with a titrated dose of testosterone gel 
(equivalent of 5 to 10 mg per day) for 6 months found that the 
higher dose caused, a reduction in negative moods, a sizable 
increase in hematocrit (from 42 to 47), and modest increases 
in arm and leg strength. Sullivan et al (2005) conducted a 
3-month study of low- or high-intensity resistance exercise 
training in men aged 65 or more, who were not hypogonadal 
(total T = 480 ng/dL or less). Some subjects also received 
a weekly i.m. injection of 100 mg testosterone enanthate. 
The addition of testosterone produced a trend toward greater 
increases overall, but the effect of testosterone appears to be 
substantial in the low-intensity training group. Considering 
that few men in the community will perform high-intensity 
training on their own, these results may indicate usefulness 
for testosterone therapy.
Three studies have reported substantial strength gains 
following testosterone treatment and all have employed doses 
of testosterone that are somewhat higher than replacement 
doses. Ferrando et al (2002) treated older hypogonadal and 
eugonadal men for 6 months with a biweekly injection of 
testosterone that was titrated to raises circulating testosterone 
into the normal range and resulted in an approximated dou-
bling of circulating testosterone (from ∼300 to ∼600 ng/dL). 
Signiﬁ  cant strength increases were observed, including a 15 
kg increase in leg extension 1-RM strength. Page et al (2005) 
treated a group of older, hypogonadal men for 36 months with 
biweekly i.m. injections of 200 mg testosterone enanthate and 
found signiﬁ  cant improvements in hand grip strength. How-
ever, the study that best demonstrates the dose dependence 
is that of Bhasin et al (2005). Both older and younger men 
were ﬁ  rst made hypogonadal with luprolide and then treated 
for 5 months with testosterone enanthate at doses ranging 
from 25 mg to 600 mg/week. Higher doses of testosterone 
produced large increases in strength, including an increase 
of 50 kg in leg press 1-RM strength in older men receiving 
a dose of 300 mg/week. The doses of 300 and 600 mg/week 
produced a high incidence of adverse effects and a dose 
of 125 mg/week was considered to be the best trade-off of 
beneﬁ  cial and adverse effects.
The dose of testosterone also appears to be critical in 
determining whether increases in bone mineral density are 
observed. Snyder et al (1999) treated older hypogonadal and 
eugonadal men for 36 months with 6 mg testosterone/day by 
patch and found that bone mineral density did not increase 
overall, but did do so in the group with the lowest pretreat-
ment testosterone levels. However, Amory et al (2004) 
treated older hypogonadal men for 36 months with biweekly 
i.m. injections of 200 mg testosterone enanthate and obtained 
substantial increases in bone mineral density, 3%–4% in the 
hip and a remarkable 10% in the lumbar spine.
Beneﬁ  cial effects of testosterone 
on the heart
The lower rate of heart disease in women has historically 
been attributed to the cardioprotective effects of estrogen. 
Presently, this position is being reexamined. The cardiopro-
tective effects of estrogen have come into some question 
and there is emerging evidence that testosterone may have 
cardioprotective effects of its own. Swartz and Young (1987) 
have shown that older men with a low circulating testoster-
one, a higher fraction have previously suffered a myocardial Clinical Interventions in Aging 2007:2(4) 564
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infarction. Testosterone supplementation in hypogonadal 
men improves exercise tolerance and decreases exercise-
associated ischemia in elderly patients with coronary artery 
disease and low (Malkin et al 2004) or low-normal (English 
et al 2000) testosterone. This protection may be secondary to 
a vasodilatory effect and/or higher pain threshold. The vaso-
dilatory effect has been conﬁ  rmed in animal models (English 
et al 2002). The beneﬁ  cial effects are seen with both acute 
(Rosano et al 1999) and chronic (English et al 2000, 2002) 
testosterone administration, and also with low (Malkin et al 
2004) and high (Rosano et al 1999) dose supplementation. 
However, none of these studies was long enough to show an 
effect on cardiovascular mortality.
Although there has been concern that testosterone therapy 
might adversely affect serum cholesterol and lipids, this con-
cern has not been bourn out in controlled studies. Wang et al 
(2000) reported that treating hypogonadal men with testos-
terone gel (equivalent of 5–10 mg per day) for 6 months did 
not produce signiﬁ  cant changes in LDL- or HDL-cholesterol. 
Whitsel et al (2001) performed a meta analysis of 19 stud-
ies involving administration of testosterone esters to older 
hypogonadal men and found that, on the whole, testosterone 
produces small, and probably offsetting, decreases in both 
HDL and LDL. An additional cardiac beneﬁ  t of testosterone 
may be seen in the ﬁ  ndings of Malkin et al (2004), who found 
that testosterone reduced circulating levels of tumor necrosis 
factor alpha and interleukin-1 beta, inﬂ  ammatory cytokines 
that are elevated in heart failure.
Risks associated with testosterone 
therapy
Risks associated with testosterone replacement in elderly 
men include ﬂ  uid retention, gynecomastia, worsening of 
sleep apnea, polycythemia and acceleration of benign or 
malignant prostatic disease (Matsumoto 2002). A high 
incidence of adverse effects was observed by Bhasin et al 
(2005) in treating older men with the very high doses of 300 
and 600 mg/week.
Among these risks, the potential effects of testosterone on 
the prostate are of the greatest concern. These concerns stem 
from the known action of testosterone in accelerating active 
prostate cancer and from the high prevalence of early-stage 
prostate cancer in elderly men. While approximately 10% 
of men will develop clinically manifest prostate cancer in 
their lifetime and ∼3% will die of the disease, autopsy data 
show that 42% of men over the age of 60 have early-stage 
prostate cancer (Mikuz 1997). Clinical trials to date are 
not large enough or long enough to determine the potential 
effects of testosterone treatment on prostate cancer. Although 
Zitzmann et al (2003) have shown that replacement and 
slightly higher doses of testosterone produce a predictable 
and moderate degree of prostate enlargement, existing data 
do not indicate that testosterone promotes prostate cancer. 
Hajjar et al (1997) treated elderly men with a replacement 
dose of testosterone and found no increase in prostate cancer 
during a 2-year follow-up. Agarwal and Oefelein (2005) 
administered testosterone for 19 months to hypogonadal 
patients with a history of prostate cancer and prostatectomy, 
but whose recent PSA levels were low. Treatment signiﬁ  -
cantly elevated circulating testosterone and improved quality 
of life without elevating PSA.
Patients should be evaluated one month after initiation of 
treatment and the dose should be increased if symptoms of 
hypogonadism have not improved. Rhoden and Morgentaler 
(2004) have reviewed the adverse effects and recommend 
the following monitoring. Safety monitoring should include 
sleep apnea, voiding symptoms, serum testosterone, PSA and 
hemoglobin or hematocrit and should be performed several 
times during the ﬁ  rst year and yearly thereafter.
Who might beneﬁ  t from 
testosterone replacement therapy?
In response to concerns over the efﬁ  cacy and risks of hor-
monal replacement in the elderly, the NIH commissioned 
an assessment by the Institute of Medicine (IOM). The IOM 
report states that there is insufﬁ  cient evidence to conclude 
that testosterone treatment in older men has well established 
beneﬁ  ts. In addition, the IOM recommended that small and 
medium-sized trials be conducted to assess the efﬁ  cacy of 
testosterone for treating muscle weakness, osteoporosis, 
sexual dysfunction, cognitive impairment and depression 
(Liverman and Blazer 2004). The IOM does not recommend 
prevention trials or trials for all hypogonadal older men. 
While we agree with these recommendations, at least two 
other avenues of exploration deserve attention.
First, while replacement doses of testosterone do not 
consistently produce substantial increases in strength, Page 
et al (2005) and Bhasin et al (2005) have shown that higher 
doses of testosterone do produce such increases. Higher doses 
of testosterone also produce more adverse effects, especially 
prostate effects. Strength, especially lower body strength, 
remains an important facto limiting the independence of older 
people. Currently, alternative strategies are being developed, 
aimed at stimulating the androgen receptor more power-
fully, without producing added adverse effects. One such 
strategy is to administer a higher dose of testosterone with Clinical Interventions in Aging 2007:2(4) 565
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the addition of a 5-alpha reductase inhibitor to prevent the 
prostate symptoms. Another strategy is the use of selective 
androgen receptor modulators (SARMs), currently under 
development at several pharmaceutical ﬁ  rms.
A second avenue where more research is needed is tes-
tosterone therapy for special populations of men who are at 
risk for development of catabolic states and muscle wasting. 
Testosterone might be used to prevent disuse muscle atrophy 
following knee or hip replacement. A study by Amory et al 
(2002) suggests that treating men with testosterone before knee 
replacement surgery improved functional independence after. 
While these results were not dramatic, one limitation of the 
study is that testosterone therapy did not continue after surgery, 
ie, during the period of muscle atrophy. In addition, hypogo-
nadism and muscle wasting are associated with a number of 
conditions that are more common in older men including COPD 
(Debigare et al 2003) , coronary artery disease (Rosano et al 
2006), glucocorticoid therapy (Salehian and Kejriwal 1999), 
and acute ischemic stoke (Jeppesen et al 1996). It is likely that in 
some cases, testosterone therapy may prevent catabolic/muscle 
wasting syndromes associated with these conditions.
In conclusion, while it is true that most studies of testoster-
one replacement in older men have not produced substantial 
increases in strength, testosterone therapy continues to hold 
promise for older men. Testosterone may be of greater use 
in special populations who are at risk for development of a 
catabolic state (eg, patients recovering from a long period of 
bed rest or joint replacement). In addition, there is promise 
that strategies will be developed to stimulate the testosterone 
pathway more robustly and to do so in a safe manner. If so, 
there may be indication for use of such therapy in a broader 
segment of the population of older men. In the meantime, truly 
hypogonadal men (those who are symptomatic men and have a 
serum testosterone concentration below 200 ng/dL) who have 
no contraindications to testosterone replacement therapy (eg, 
prostate cancer) may beneﬁ  t from testosterone replacement 
regardless of whether they are 30 or 80 years of age.
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